Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of rivoceranib and
paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed
standard treatment with imatinib, sunitinib, and regorafenib.